Biofrontera (BFRI) Fundamental Analysis: Revenue, Earnings & Valuation

5.31 / 10

Netural

Fundamental analysis rates the company Neutral (5.3/10). Strengths include high inventory turnover, low cost‑of‑sales ratio and solid interest coverage. Weaknesses are elevated long‑term debt to working capital and high current‑liabilities ratio. Overall, fundamentals are moderate with limited growth impetus.

Analysis Checks(5/10)

Revenue-MV

Value2.36

Score2/3

Weight23.35%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value11.75

Score1/3

Weight-1.44%

1M Return-0.38%

Inventory turnover ratio

Value2.72

Score3/3

Weight-3.62%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value65.78

Score1/3

Weight-5.87%

1M Return-1.69%

PB-ROE

Value-0.89

Score1/3

Weight29.75%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value1.00

Score1/3

Weight-2.47%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.27%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value11.75

Score1/3

Weight-1.13%

1M Return-0.30%

Cost of sales ratio (%)

Value26.29

Score3/3

Weight1.07%

1M Return0.26%

Asset-MV

Value-0.55

Score3/3

Weight64.64%

1M Return11.61%

Is BFRI fundamentally strong?

BFRI scores 5.31/10 on fundamentals and holds a Fair valuation at present. Backed by its -141.30% ROE, -25.26% net margin, -1.08 P/E ratio, 1.09 P/B ratio, and 67.70% earnings growth, these metrics solidify its Netural investment rating.